Condition
Oligometastatic Renal Cell Carcinoma
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Active Not Recruiting1
Unknown1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06004336Phase 2RecruitingPrimary
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
NCT02956798Phase 2Active Not RecruitingPrimary
SAbR For Oligometastatic Renal Cell Carcinoma
NCT05578664Phase 2UnknownPrimary
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
Showing all 3 trials